drugset / Trial / NCT06835504
Morphine or Ketamine for Analgesia
Phase 3
Not yet recruiting
1010 enrolled
Columbia University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2029-08-30
- Completion
- 2030-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.25 mg/kg | Intravenous |
| Comparator | Morphine | Other / unclassified | 0.1 mg/kg | Intravenous |
Indications
No indication recorded.